About US
Contact us
-
J&J's struggling Invokana slashes heart, kidney risks in latest trial winSAN FRANCISCO—Johnson & Johnson and its fellow SGLT2 drug makers are all working to show benefits for patients with kidney disease. But in that group, J&J can tout data its rivals don’t have.2019/6/6
-
Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter salesAfter undershooting analyst sales forecasts in the first quarter, Eli Lilly’s psoriasis drug Taltz is on the hot seat in an immunology market packed with blockbusters. Lilly is hoping some new data on2019/6/6
-
Lilly, Boehringer's DPP-4 drug Tradjenta ties generic rival in heart safety studySAN FRANCISCO—Boehringer Ingelheim and Eli Lilly have already shown that Tradjenta doesn’t hurt patients’ hearts. But the pair is back with even more supporting evidence that they hopewill bolster th2019/6/5
-
How to correct opioid misinformation? Spend $285M on countermarketing, expert says in J&J trialCountless lawsuits have sought to estimate thecosts of fixing the U.S. opioid and addiction epidemic. Now, thanks to an expert in Oklahoma's ongoing trial against Johnson & Johnson, we have one d2019/6/5
-
Roche snags first-in-class FDA nod for lymphoma drug PolivyRoche has a trio of lucrative cancer blockbusters coming under a growing biosimilar attack, but now the company has scored an FDA nod for its latest cancer launch—and it's a first-in-class drug for2019/6/4
-
PTC scores new Emflaza approval in DMD patients 2 and olderDuchenne muscular dystrophy (DMD) drug Emflaza had a controversial past under its previous owner, butits current captain, PTC Therapeutics, is forging ahead—and a new FDA approval could help. T2019/6/4
-
ASCO: J&J pads case for new Erleada use with prostate cancer survival dataCHICAGO—Johnson & Johnson’s Erleada may be thefollow-up to blockbuster Zytiga, but it’s also ready to go where its predecessor hasn’t gone before. Friday at the American Society of Clinical Oncol2019/6/3
-
ASCO: Merck details Keytruda's second stomach cancer slipCHICAGO—Last month, Merck revealed that its Keytruda immunotherapy had run into more trouble in stomach cancer, a disease that’s given it difficultyin the past. And it shared the details of that stum2019/6/3
-
ASCO: Forget lung cancer history. Merck's Keytruda shatters the stats on long-term survivalCHICAGO—Before the dawn of immunotherapy, long-term survival was almost a foreign concept in the metastatic lung cancer arena. But Saturday, that’s just what Merck showed Keytruda could produce. At t2019/5/31
-
ASCO: Novartis' Kisqali posts first-in-class survival win in younger womenCHICAGO—Even before it launched, Novartis’ Kisqali was living in the shadow of classmate Ibrance, and it has been ever since. But with its latest data set, Kisqali now has an advantage the Pfizer blo2019/5/31